# Enfusion 4Q 2022 Shareholder Letter

March 2023



## Disclaimer

## Forward-Looking Statements

Statements we make in this presentation may include statements which are not historical facts and are considered forwardlooking within the meaning of Section 27A of the Securities Act of 1933 (Securities Act) and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), including expectations regarding future financial performance. These forward-looking statements are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "could," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions.

These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, such as those set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 that was filed with the SEC on March 30, 2022 and our subsequent Quarterly Reports on Form 10-Q. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.



### Dear Shareholders,

Enfusion ended 2022 – its first full calendar year after the IPO – on a high note. During volatile market conditions, the resiliency of our business tends to shine and accentuate the value we provide to our clients. Investment managers have been reimagining their technology infrastructure without a clear solution. Many have selected Enfusion's software and services as a strategic solution to transform their legacy systems with our robust, contiguous cloud native end to end software platform.

4Q22 Highlights: This quarter's performance demonstrates our focus on delivering best-in class "software-and-a-service" offerings. Two key areas I'm particularly proud of:

- We delivered robust financial results despite a challenging macro environment. Our fourth quarter top line outperformance was driven by strength in new sales across all products and services. These revenue results, coupled with our ongoing expense discipline, translated into significant YoY adjusted EBITDA margin expansion. We also delivered a second consecutive quarter of positive adjusted free cash flow driven by healthy margin and cash conversion.
- Our fourth quarter client wins demonstrate the regional and operational diversification of our addressable market. During the quarter, we signed a multi-billion-dollar Tokyo-based alternative investment manager that was looking to modernize its inefficient, on-prem legacy stack. We also partnered with a newly formed spin-out from one of the Middle-East's largest global hedge funds seeking a robust cloud-native platform. Further, we're particularly proud that a North Carolina-based university endowment selected Enfusion to replace its outdated legacy infrastructure, allowing them to support all asset classes and reduce total cost of ownership.

Entering 2023, we expect to build on our momentum and further advance Enfusion's leadership position as the premier provider of end-to-end cloud-native investment management solution. Our capital allocation strategy remain sharply focused on technology, product and client services in order to provide innovative solutions and further enhance the scope and quality of our client services experience. We believe our investments in these categories will further our competitive advantage by accelerating innovation, bringing new products capabilities to market and providing an unparalleled client experience.

I want to express my gratitude to my colleagues for their hard work, dedication to our clients and passion for our brand. Our results this quarter speak to the strength of our talent and commitment of our team to serving our clients every day.

Sincerely,

**Oleg Movchan** 

**Chief Executive Officer** 



## Our mission

To help solve investment managers' evolving business and operational challenges through next generation technology





# We simplify and unify the

# investment management lifecycle

We manage complex workflows...

Fills


Orders


Reconciliations

Allocated Trades

Reporting

Statements







# Serving clients across the investment management industry

Alternative Investment Managers							
Hedge Funds	Private Equity						
Private Credit	Family Offices						






## Purpose-built end-to-end solution

### Mission critical systems integrated with a suite of technology-powered services

#### Portfolio Management System **Analytics** • Live details of portfolio positions OEMS Connected in real-time Real-time Investment with our PMS and OEMS Book of Record ("IBOR") Investment • Comprehensive client **Decision** data insights to analyze portfolios through time **Order Execution** horizons and automate **Management System** Order Visual customized visualized reports Generation **Analytics** • Electronically communicate and manage trade orders One single • Systemically enforce trading regulations and dataset and Accounting / internal guidelines **General Ledger** source of truth Order/Trade Reporting Double-entry ledger that & Analytics Routing automates the posting of Technology-Powered general ledger journal enfusion entries directly from PMS Services Phalytics • Complete, real-time • Expert teams empowered Accounting Book of by technology Admin. & Settlement Allocations Trade Affirmation Record ("ABOR") • Front-, middle- and backoffice time consuming, administrative tasks Accounting / General Accounting / General Los



# Addressing a large and growing market



# Robust growth in Underlying industry

40% total growth

in global AUM 2015-2020

8% annual growth

of alternatives AUM projected

6% annual growth

of total AUM projected

\$145 trillion

in global AUM by 2025



## Why we win





One end-to-end solution, one single dataset and source of truth



Rapid pace of delivery and evolution



Open, flexible and tailored



Cloud-native, multi-tenant SaaS



Drive efficiencies and lower total cost of ownership

Unique ability to lead with a single solution – and then adjust to a client's growing complexity, scale with its size, evolve with its operational workflows, and continuously adapt to customer business dynamics



## Q4 2022 key financial highlights

\$ in millions

Highly attractive
SaaS model with
combination of
scale, growth and
profitability

Total Revenue	\$40.5	27.2% YoY Growth
Gross Profit	\$27.2	67.2%
Adjusted Gross Profit <sup>(1)</sup>	\$27.5	68.0% Adjusted Gross Margin
Net Income	\$0.8	1.9% Net income Margin
Adjusted EBITDA <sup>(1)</sup>	\$6.8	16.7% Adjusted EBITDA Margin
Operating Cash Flow	\$7.5	18.6% OCF Margin
Adjusted Free Cash Flow	\$3.6	53.4% FCF Conversion

(1) See appendix for definition and non-GAAP reconciliations.




# Strong growth trends with expanding profitability





# Organic, sticky expansion at scale

\$ in millions





## Financial outlook

	2023E
Revenue	\$185–\$190 million
Adjusted EBITDA	\$32–\$34 million

These statements are forward-looking and actual results may differ materially. Refer to the "Forward-Looking Statements" safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

Enfusion has not reconciled its estimates for Adjusted EBITDA to net income under U.S. generally accepted accounting principles (GAAP) due to the uncertainty and potential variability of expenses that may be incurred in the future. Accordingly, a reconciliation is not available without unreasonable effort.




13

<sup>\*</sup>Adjusted EBITDA guidance excludes stock-based compensation of \$12 million for the full year 2023.

# Appendix

. . .



## ENFUSION, INC. CONSOLIDATED BALANCE SHEETS (dollars in thousands, except shares and unit amounts and par value) (Unaudited)

	December 31,			
		2022		2021
ASSETS				
Current Assets:				
Cash and cash equivalents	\$	62,545	\$	64,365
Accounts receivable, net		25,855		18,223
Prepaid expenses		6,105		6,030
Other current assets		2,303		1,060
Total current assets		96,808		89,678
Property and equipment, net		15,759		13,051
Right of use asset		6,732		_
Other assets		4,484		3,356
Total assets	\$	123,783	\$	106,085
LIABILITIES AND STOCKHOLDERS' EQUITY				
Current liabilities:				
Accounts payable	\$	1,685	\$	2,528
Accrued expenses and other current liabilities	•	11,665	<b>T</b>	5,578
Lease liability - short term		4,030		
Total current liabilities		17,380		8,106
Lease liability		2,959		
Other liabilities		<del></del>		538
Total liabilities	_	20,339		8,644
Stockholders' Equity:		,		,
Class A common stock, \$0.001 par value; 1,000,000,000 shares authorized, 70,859,711 and 65,583,289 shares				
issued and outstanding as of December 31, 2022 and December 31, 2021, respectively		71		66
Class B common stock, \$0.001 par value; 150,000,000 shares authorized, 43,198,768 and 47,470,972 shares issued				
and outstanding as of December 31, 2022 and December 31, 2021, respectively		43		47
Additional paid-in capital		244,260		226,717
Accumulated deficit		(178,863)		(171,209)
Accumulated other comprehensive loss		(504)		(325)
Total stockholders' equity attributable to Enfusion, Inc.		65,007		55,296
Non-controlling interests		38,437		42,145
Total stockholders' equity		103,444		97,441
Total liabilities and stockholders' equity	\$	123,783	\$	106,085
			_	



# ENFUSION. INC. CONSOLIDATED STATEMENTS OF OPERATIONS (dollars in thousands) (Unaudited)

	Three Months Ended December 31		Years Ended December 31			mber 31	
		2022	2021		2022		2021
REVENUES:							
Platform subscriptions	\$	37,804	29,562	\$	138,868	\$	103,259
Managed services		2,691	1,979		9,821		7,119
Other		22	312		1,660		1,322
Total revenues		40,517	31,853		150,349		111,700
COST OF REVENUES:							
Platform subscriptions		11,564	8,656		40,017		27,195
Managed services		1,633	1,457		6,692		4,425
Other		99	51		391		225
Total cost of revenues		13,296	10,164		47,100		31,845
Gross profit		27,221	21,689		103,249		79,855
OPERATING EXPENSES:							
General and administrative		15,073	128,229		68,764		150,614
Sales and marketing		6,001	39,402		29,286		51,725
Technology and development		4,775	146,556		17,163		153,400
Total operating expenses		25,849	314,187		115,213		355,739
Income (loss) from operations		1,372	(292,498)		(11,964)		(275,884)
NON-OPERATING (EXPENSE) INCOME:							
Interest expense		424	(307)		413		(4,594)
Other (expense) income		(590)	(1,214)		(638)		(1,185)
Total non-operating expense		(166)	(1,521)		(225)		(5,779)
Income (loss) before income taxes		1,206	(294,019)		(12,189)		(281,663)
Income taxes		418	(125)		1,074		579
Net income (loss)		788	(293,894)	\$	(13,263)	\$	(282,242)
Net income (loss) per Class A common share attributable to Enfusion, Inc.:							
Basic		0.01	(2.26)		(0.10)		(2.26)
Diluted		0.01	(2.26)		(0.10)		(2.26)
Weighted Average number of Class A common shares outstanding:							
Basic		88,022	83,045		85,393		83,045
Diluted		132,950	83,045		85,393		83,045



# ENFUSION. INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (dollars in thousands) (Unaudited)

	2022		2021	
Cash flows from operating activities:				
Net (loss) income	\$ (13,263)	\$	(282,242)	
Adjustments to reconcile net (loss) income to net cash provided by operating activities:				
Non-cash operating lease expense	257			
Depreciation and amortization	6,344		3,975	
Provision for bad debts	1,399		1,450	
Amortization of debt-related costs	26		222	
Stock-based compensation expense	24,993		289,803	
Loss on extinguishment of debt	<del></del>		1,215	
Net foreign currency losses				
Change in operating assets and liabilities:				
Accounts receivable	(9,031)		(7,493)	
Prepaid expenses and other current assets	(1,767)		(6,477)	
Accounts payable	(843)		2,044	
Accrued expenses and other liabilities	 6,041		(2,815)	
Net cash provided by (used in) operating activities	14,156		(318)	
Cash flows from investing activities:				
Purchases of property and equipment	 (7,931)		(8,014)	
Net cash used in investing activities	(7,931)		(8,014)	
Cash flows from financing activities:				
Repayment of term loan	<u>—</u>		(100,000)	
Payment of Member distributions			(3,283)	
Issuance of Class A common stock in the IPO, net of issuance costs	<u>—</u>		260,545	
Purchases of common units from Pre-IPO common unit holders			(87,846)	
Payment of withholding taxes on stock-based compensation	(7,959)		(10,567)	
Net cash (used in) provided by financing activities	(7,959)		58,849	
Effect of exchange rate changes on cash	 (86)		(90)	
Net (decrease) increase in cash and cash equivalents	(1,820)		50,427	
Cash and cash equivalents, beginning of period	 64,365		13,938	
Cash and cash equivalents, end of period	\$ 62,545	\$	64,365	



## Reconciliations To Non-GAAP Financial Measures

The following table reconciles gross profit to adjusted gross profit:

	 Three Months Ended							
(\$ in thousands)	 December 31, 2021	March 30, 2022	June 30, 2022	<b>September 30, 2022</b>	<b>December 31, 2022</b>			
GAAP Gross profit	\$ 21,689	23,158	25,693	27,177	27,221			
Add back stock based compensation expense	 377	354	341	406	321			
Adjusted Gross profit	 22,066	23,512	26,034	27,583	27,542			
Adjusted Gross Margin	69.3%	68.9%	71.2%	70.5%	68.0%			

The following table reconciles net income to Adjusted EBITDA:

		Th	nree Months Ended		
(\$ in thousands)	<b>December 31, 2021</b>	March 30, 2022	<b>June 30, 2022</b>	<b>September 30, 2022</b>	<b>December 31, 2022</b>
Net income (loss)	\$ (293,894)	(12,524)	(4,125)	2,598	788
Interest expense	307	6	1	4	(424)
Income taxes	(125)	150	219	287	418
Depreciation and amortization	1,316	1,340	1,615	1,699	1,690
EBITDA	(292,396)	(11,028)	(2,290)	4,588	2,472
Adjustments:					
Stock-based compensation expense	289,803	12,432	7,523	833	4,205
Loss on debt extinguishment	1,215				
Tax payment on stock-based compensation	4,570	434	50	14	87
Adjusted EBITDA	3,192	1,838	5,283	5,435	6,764
Adjusted EBITDA margin	10.0%	5.4%	14.5%	13.9%	16.7%



## Reconciliations of Non-GAAP Financial Measures

The following table reconciles operating cash flow to unlevered free cash flow and adjusted free cash flow:

		Three Months Ended							
(\$ in thousands)	Decen	nber 31, 2021	March 31, 2022	June 30, 2022	<b>September 30, 2022</b>	<b>December 31, 2022</b>			
Net Cash provided by (used in) operating activities	\$	(5,812)	(4,097)	2,890	7,842	7,521			
Purchase of property and equipment		(1,641)	(3,171)	(2,092)	(922)	(1,746)			
Unlevered Free Cashflow		(7,453)	(7,268)	798	6,920	5,775			
Adjustments									
Less bonus timing and non-recurring expenses		4,389	(2,160)	(2,160)	(2,160)	(2,160)			
				. <u></u>					
Adjusted Free Cash Flow		(3,064)	(9,428)	(1,362)	4,760	3,615			

The Company's stock compensation expense was recognized in the following captions within the consolidated statements of operations:

	Three Months Ended			Year Ended December 31,		
(\$ in thousands)		December 31, 2022		2022		
Cost of revenues	\$	321	\$	1,421		
General and administrative		2,096		14,130		
Sales and marketing		936		5,875		
Technology and development		852		3,567		
Total stock compensation expense	\$	4,205	\$	24,993		



## Definitions

#### Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with GAAP, this presentation and the accompanying tables include Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit, Adjusted Gross Margin, Unlevered Free Cash Flow, and Adjusted Free Cash Flow, which are non-GAAP financial measures. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP.

Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit, Adjusted Gross Margin, Unlevered Free Cash Flow, and Adjusted Free Cash Flow are supplemental measures of our operating performance and liquidity that are neither required by, nor presented in accordance with, U.S. GAAP, and our calculations thereof may not be comparable to similarly titled measures reported by other companies.

These measures are presented because they are the primary measures used by management to evaluate our financial performance and liquidity, and for forecasting purposes. This non-GAAP financial information is useful to investors because it eliminates certain items that affect period-over-period comparability and provides consistency with past financial performance or liquidity and additional information about underlying results and trends by excluding certain items that may not be indicative of our business, results of operations or outlook. Additionally, we believe that these and similar measures are often used by securities analysts, investors and other interested parties as a means of evaluating a company's operating performance.

Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit, Adjusted Gross Margin, Unlevered Free Cash Flow, and Adjusted Free Cash Flow are non-GAAP financial measures, are not measurements of our financial performance or liquidity under U.S. GAAP and should not be considered as alternatives to net income, income from operations, gross profit, gross margin, or any other performance measures determined in accordance with U.S. GAAP. These non-GAAP financial measures have limitations as analytical tools and you should not consider them in isolation or as substitutes for analysis of our results as reported under GAAP, but rather as supplemental information to our business results. In addition, these non-GAAP financial measures may not be comparable to similarly titled measures of other companies due to potential differences in methods of calculation and items or events being adjusted. Furthermore, other companies may use different measures to evaluate their performance, all of which could reduce the usefulness of these non-GAAP financial measures as tools for comparison.

### Adjusted EBITDA and Adjusted EBITDA Margin

Adjusted EBITDA represents earnings before interest, taxes, depreciation and amortization, adjusted to exclude certain items of a non-recurring or unusual nature, including payments to repurchase management incentive awards from our Change in Control Bonus Plan, initial public offering costs, and stock-based compensation expense. Adjusted EBITDA divided by total net revenues.

#### **Unlevered Free Cash Flow**

Unlevered Free Cash Flow represents net cash provided from operating activities less purchases of property and equipment and other assets, plus cash interest expense. However, given our non-discretionary expenditures, Unlevered Free Cash Flow does not represent residual cash flow available for discretionary expenditures.

### **Adjusted Free Cash Flow**

Adjusted Free Cash Flow represents Unlevered Free Cash Flow adjusted to exclude certain annual employee bonuses that are amortized on a quarterly basis as well as certain items of a non-recurring or unusual nature.

### Adjusted Gross Profit and Adjusted Gross Margin

Adjusted Gross Profit represents gross profit, excluding the impact of stock-based compensation. Adjusted Gross Margin represents Adjusted Gross Profit divided by total net revenues.



## **Definitions Continued**

#### **Key Metrics:**

In connection with the management of our business, we identify, measure and assess a variety of key metrics. The key metrics we use in managing our business are set forth below.

#### **Annual Recurring Revenue**

We calculate Annual Recurring Revenue, or ARR, by annualizing platform subscriptions and managed services revenues recognized in the last month of the measurement period. We believe ARR provides important information about our future revenue potential, our ability to acquire new clients and our ability to maintain and expand our relationship with existing clients. ARR is included in a set of metrics we calculate monthly to review with management as well as periodically with our board of directors.

#### **Net Dollar Retention Rate**

We calculate Net Dollar Retention Rate as of a period end by starting with the ARR for all clients as of twelve months prior to such period end, or Prior Period ARR. We then calculate the ARR from those same clients as of the current period end, or Current Period ARR. Current Period ARR includes expansion within existing clients inclusive of contraction and voluntary attrition, but excludes involuntary cancellations. We define involuntary cancellations as accounts that were cancelled due to the client no longer being in business. We identify involuntary cancellations to be excluded from our Net Dollar Retention Rate calculation based on representations made by the client at the time of cancellation.

Our Net Dollar Retention Rate is equal to the Current Period ARR divided by the Prior Period ARR. We believe Net Dollar Retention Rate is an important metric because, in addition to providing a measure of retention, it indicates our ability to grow revenues within existing client accounts.

### **Average Contract Value**

We calculate Average Contract Value, or ACV, by dividing ARR by the number of clients that are billed at the end of the measurement period. We believe ACV is an important metric because it provides important information about the growth of our clients' accounts.

Investors should not place undue reliance on ARR or Net Dollar Retention Rate or Average Contract Value as an indicator of future or expected results. Our presentation of these metrics may differ from similarly titled metrics presented by other companies and therefore comparability may be limited.

